Drug lookup | Fillwise

Accel-Rizatriptan ODT · DIN 02483270 · 5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Accel-Rizatriptan ODT · DIN 02483270 Manufacturer: Accel Pharma Inc.; listing date 2020-01-31 Health Canada: Marketed since 2019-10-07 · brand ACCEL-RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5 MG · company Accel pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Accel-Rizatriptan ODT: Formulary list price $7.7800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $7.7800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97371 · Verify on the e-Formulary ↗ (DIN 02483270)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02483270). DIN 02483270: Accel-Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200047; group id 544; item number 1466; lccId None; manufacturer id ACC Source form: Orally Disintegrating Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $7.7800; ministry $7.7800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02483270 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97371

Interchangeable products

Apo-Rizatriptan RPD · DIN 02393484 · $11.1150 CCP-Rizatriptan · DIN 02458764 · $11.1150 Co Rizatriptan ODT · DIN 02374730 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465086 · $11.1150 Mar-Rizatriptan ODT · DIN 02462788 · $11.1150 Maxalt RPD · DIN 02240518 · $11.1650 Mint-Rizatriptan ODT · DIN 02439573 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379198 · $11.1150 Nat-Rizatriptan ODT · DIN 02436604 · $11.1650 PMS-Rizatriptan RDT · DIN 02393360 · $11.1150 Rizatriptan ODT · DIN 02442906 · $11.1150 Rizatriptan ODT · DIN 02446111 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351870 · $11.1150 Teva-Rizatriptan ODT · DIN 02396661 · $11.1150

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02483270

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Rizatriptan ODT · DIN 02465086 · 5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp-Rizatriptan ODT · DIN 02465086 Manufacturer: Jamp Pharma Corporation; listing date 2018-06-29 Health Canada: Marketed since 2018-02-12 · brand JAMP-RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp-Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95327 · Verify on the e-Formulary ↗ (DIN 02465086)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02465086). DIN 02465086: Jamp-Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200047; group id 544; item number 1466; lccId None; manufacturer id JPC Source form: Orally Disintegrating Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02465086 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95327

Interchangeable products

Accel-Rizatriptan ODT · DIN 02483270 · $7.7800 Apo-Rizatriptan RPD · DIN 02393484 · $11.1150 CCP-Rizatriptan · DIN 02458764 · $11.1150 Co Rizatriptan ODT · DIN 02374730 · $11.1150 Mar-Rizatriptan ODT · DIN 02462788 · $11.1150 Maxalt RPD · DIN 02240518 · $11.1650 Mint-Rizatriptan ODT · DIN 02439573 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379198 · $11.1150 Nat-Rizatriptan ODT · DIN 02436604 · $11.1650 PMS-Rizatriptan RDT · DIN 02393360 · $11.1150 Rizatriptan ODT · DIN 02442906 · $11.1150 Rizatriptan ODT · DIN 02446111 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351870 · $11.1150 Teva-Rizatriptan ODT · DIN 02396661 · $11.1150

Shortage status: resolved shortage (ended 2021-05-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02465086

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Rizatriptan ODT · DIN 02462788 · 5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mar-Rizatriptan ODT · DIN 02462788 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2018-04-30 Health Canada: Marketed since 2018-02-15 · brand MAR-RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5 MG · company Marcan pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mar-Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95062 · Verify on the e-Formulary ↗ (DIN 02462788)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02462788). DIN 02462788: Mar-Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200047; group id 544; item number 1466; lccId None; manufacturer id MAR Source form: Orally Disintegrating Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02462788 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95062

Interchangeable products

Accel-Rizatriptan ODT · DIN 02483270 · $7.7800 Apo-Rizatriptan RPD · DIN 02393484 · $11.1150 CCP-Rizatriptan · DIN 02458764 · $11.1150 Co Rizatriptan ODT · DIN 02374730 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465086 · $11.1150 Maxalt RPD · DIN 02240518 · $11.1650 Mint-Rizatriptan ODT · DIN 02439573 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379198 · $11.1150 Nat-Rizatriptan ODT · DIN 02436604 · $11.1650 PMS-Rizatriptan RDT · DIN 02393360 · $11.1150 Rizatriptan ODT · DIN 02442906 · $11.1150 Rizatriptan ODT · DIN 02446111 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351870 · $11.1150 Teva-Rizatriptan ODT · DIN 02396661 · $11.1150

Shortage status: resolved shortage (ended 2020-09-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02462788

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Maxalt RPD · DIN 02240518 · 5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

How long EAP takes

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Savings card: RxHelp ONE lists Maxalt RPD (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Maxalt RPD · DIN 02240518 Manufacturer: Organon Canada Inc.; listing date 2012-03-26 Health Canada: Marketed since 2023-05-29 · brand MAXALT RPD · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5 MG · company Organon canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $11.1650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64089 · Verify on the e-Formulary ↗ (DIN 02240518)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02240518). DIN 02240518: Maxalt RPD Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200047; group id 544; item number 1466; lccId None; manufacturer id OCI Source form: Orally Disintegrating Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $23.6888; ministry $11.1650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240518 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64089

Interchangeable products

Accel-Rizatriptan ODT · DIN 02483270 · $7.7800 Apo-Rizatriptan RPD · DIN 02393484 · $11.1150 CCP-Rizatriptan · DIN 02458764 · $11.1150 Co Rizatriptan ODT · DIN 02374730 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465086 · $11.1150 Mar-Rizatriptan ODT · DIN 02462788 · $11.1150 Mint-Rizatriptan ODT · DIN 02439573 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379198 · $11.1150 Nat-Rizatriptan ODT · DIN 02436604 · $11.1650 PMS-Rizatriptan RDT · DIN 02393360 · $11.1150 Rizatriptan ODT · DIN 02442906 · $11.1150 Rizatriptan ODT · DIN 02446111 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351870 · $11.1150 Teva-Rizatriptan ODT · DIN 02396661 · $11.1150

Shortage status: resolved shortage (ended 2023-05-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240518

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Rizatriptan ODT · DIN 02379198 · 5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mylan-Rizatriptan ODT · DIN 02379198 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2012-03-26 Health Canada: Marketed since 2012-01-31 · brand MYLAN-RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5 MG · company Mylan pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Mylan-Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86508 · Verify on the e-Formulary ↗ (DIN 02379198)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02379198). DIN 02379198: Mylan-Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200047; group id 544; item number 1466; lccId None; manufacturer id MYL Source form: Orally Disintegrating Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02379198 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86508

Interchangeable products

Accel-Rizatriptan ODT · DIN 02483270 · $7.7800 Apo-Rizatriptan RPD · DIN 02393484 · $11.1150 CCP-Rizatriptan · DIN 02458764 · $11.1150 Co Rizatriptan ODT · DIN 02374730 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465086 · $11.1150 Mar-Rizatriptan ODT · DIN 02462788 · $11.1150 Maxalt RPD · DIN 02240518 · $11.1650 Mint-Rizatriptan ODT · DIN 02439573 · $11.1150 Nat-Rizatriptan ODT · DIN 02436604 · $11.1650 PMS-Rizatriptan RDT · DIN 02393360 · $11.1150 Rizatriptan ODT · DIN 02442906 · $11.1150 Rizatriptan ODT · DIN 02446111 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351870 · $11.1150 Teva-Rizatriptan ODT · DIN 02396661 · $11.1150

Shortage status: active shortage (reported 2026-02-02, estimated to end 2027-02-09, last updated 2026-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02379198

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Rizatriptan RDT · DIN 02393360 · 5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Rizatriptan RDT · DIN 02393360 Manufacturer: Pharmascience Inc.; listing date 2012-12-21 Health Canada: Marketed since 2012-10-30 · brand PMS-RIZATRIPTAN RDT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Rizatriptan RDT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87859 · Verify on the e-Formulary ↗ (DIN 02393360)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02393360). DIN 02393360: PMS-Rizatriptan RDT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200047; group id 544; item number 1466; lccId None; manufacturer id PMS Source form: Orally Disintegrating Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02393360 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87859

Interchangeable products

Accel-Rizatriptan ODT · DIN 02483270 · $7.7800 Apo-Rizatriptan RPD · DIN 02393484 · $11.1150 CCP-Rizatriptan · DIN 02458764 · $11.1150 Co Rizatriptan ODT · DIN 02374730 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465086 · $11.1150 Mar-Rizatriptan ODT · DIN 02462788 · $11.1150 Maxalt RPD · DIN 02240518 · $11.1650 Mint-Rizatriptan ODT · DIN 02439573 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379198 · $11.1150 Nat-Rizatriptan ODT · DIN 02436604 · $11.1650 Rizatriptan ODT · DIN 02442906 · $11.1150 Rizatriptan ODT · DIN 02446111 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351870 · $11.1150 Teva-Rizatriptan ODT · DIN 02396661 · $11.1150

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02393360

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rizatriptan ODT · DIN 02442906 · 5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Rizatriptan ODT · DIN 02442906 Manufacturer: Sanis Health Inc.; listing date 2020-08-28 Health Canada: Marketed since 2015-07-23 · brand RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92741 · Verify on the e-Formulary ↗ (DIN 02442906)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02442906). DIN 02442906: Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200047; group id 544; item number 1466; lccId None; manufacturer id SAI Source form: Orally Disintegrating Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442906 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92741

Interchangeable products

Accel-Rizatriptan ODT · DIN 02483270 · $7.7800 Apo-Rizatriptan RPD · DIN 02393484 · $11.1150 CCP-Rizatriptan · DIN 02458764 · $11.1150 Co Rizatriptan ODT · DIN 02374730 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465086 · $11.1150 Mar-Rizatriptan ODT · DIN 02462788 · $11.1150 Maxalt RPD · DIN 02240518 · $11.1650 Mint-Rizatriptan ODT · DIN 02439573 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379198 · $11.1150 Nat-Rizatriptan ODT · DIN 02436604 · $11.1650 PMS-Rizatriptan RDT · DIN 02393360 · $11.1150 Rizatriptan ODT · DIN 02446111 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351870 · $11.1150 Teva-Rizatriptan ODT · DIN 02396661 · $11.1150

Shortage status: resolved shortage (ended 2025-02-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442906

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rizatriptan ODT · DIN 02446111 · 5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Rizatriptan ODT · DIN 02446111 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30 Health Canada: Marketed since 2018-02-13 · brand RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93138 · Verify on the e-Formulary ↗ (DIN 02446111)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02446111). DIN 02446111: Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200047; group id 544; item number 1466; lccId None; manufacturer id SIV Source form: Orally Disintegrating Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02446111 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93138

Interchangeable products

Accel-Rizatriptan ODT · DIN 02483270 · $7.7800 Apo-Rizatriptan RPD · DIN 02393484 · $11.1150 CCP-Rizatriptan · DIN 02458764 · $11.1150 Co Rizatriptan ODT · DIN 02374730 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465086 · $11.1150 Mar-Rizatriptan ODT · DIN 02462788 · $11.1150 Maxalt RPD · DIN 02240518 · $11.1650 Mint-Rizatriptan ODT · DIN 02439573 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379198 · $11.1150 Nat-Rizatriptan ODT · DIN 02436604 · $11.1650 PMS-Rizatriptan RDT · DIN 02393360 · $11.1150 Rizatriptan ODT · DIN 02442906 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351870 · $11.1150 Teva-Rizatriptan ODT · DIN 02396661 · $11.1150

Shortage status: resolved shortage (ended 2019-02-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02446111

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Rizatriptan ODT · DIN 02351870 · 5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Rizatriptan ODT · DIN 02351870 Manufacturer: Sandoz Canada Inc.; listing date 2012-03-26 Health Canada: Marketed since 2012-01-30 · brand SANDOZ RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83711 · Verify on the e-Formulary ↗ (DIN 02351870)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02351870). DIN 02351870: Sandoz Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200047; group id 544; item number 1466; lccId None; manufacturer id SDZ Source form: Orally Disintegrating Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351870 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83711

Interchangeable products

Accel-Rizatriptan ODT · DIN 02483270 · $7.7800 Apo-Rizatriptan RPD · DIN 02393484 · $11.1150 CCP-Rizatriptan · DIN 02458764 · $11.1150 Co Rizatriptan ODT · DIN 02374730 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465086 · $11.1150 Mar-Rizatriptan ODT · DIN 02462788 · $11.1150 Maxalt RPD · DIN 02240518 · $11.1650 Mint-Rizatriptan ODT · DIN 02439573 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379198 · $11.1150 Nat-Rizatriptan ODT · DIN 02436604 · $11.1650 PMS-Rizatriptan RDT · DIN 02393360 · $11.1150 Rizatriptan ODT · DIN 02442906 · $11.1150 Rizatriptan ODT · DIN 02446111 · $11.1150 Teva-Rizatriptan ODT · DIN 02396661 · $11.1150

Shortage status: resolved shortage (ended 2025-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02351870

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Rizatriptan ODT · DIN 02396661 · 5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Rizatriptan ODT · DIN 02396661 Manufacturer: Teva Canada Limited; listing date 2014-12-18 Health Canada: Marketed since 2014-11-04 · brand TEVA-RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88170 · Verify on the e-Formulary ↗ (DIN 02396661)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02396661). DIN 02396661: Teva-Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200047; group id 544; item number 1466; lccId None; manufacturer id TEV Source form: Orally Disintegrating Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02396661 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88170

Interchangeable products

Accel-Rizatriptan ODT · DIN 02483270 · $7.7800 Apo-Rizatriptan RPD · DIN 02393484 · $11.1150 CCP-Rizatriptan · DIN 02458764 · $11.1150 Co Rizatriptan ODT · DIN 02374730 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465086 · $11.1150 Mar-Rizatriptan ODT · DIN 02462788 · $11.1150 Maxalt RPD · DIN 02240518 · $11.1650 Mint-Rizatriptan ODT · DIN 02439573 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379198 · $11.1150 Nat-Rizatriptan ODT · DIN 02436604 · $11.1650 PMS-Rizatriptan RDT · DIN 02393360 · $11.1150 Rizatriptan ODT · DIN 02442906 · $11.1150 Rizatriptan ODT · DIN 02446111 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351870 · $11.1150

Shortage status: resolved shortage (ended 2023-04-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02396661

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Rizatriptan · DIN 02393468 · 5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

1 brand, same coverage

Apo-Rizatriptan · DIN 02393468 Manufacturer: Apotex Inc.; listing date 2012-12-21 Health Canada: Marketed since 2013-03-06 · brand APO-RIZATRIPTAN · ATC N02CC04 RIZATRIPTAN · form Tablet · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Rizatriptan: Formulary list price $12.5970/unit (unit not stated in source; not the patient's cost)

Ministry pays: $12.5970 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87868 · Verify on the e-Formulary ↗ (DIN 02393468)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02393468). DIN 02393468: Apo-Rizatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200045; group id 544; item number 1468; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $12.5970; ministry $12.5970 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02393468 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87868

Interchangeable products

Jamp-Rizatriptan · DIN 02380455 · $11.1150 Jamp-Rizatriptan IR · DIN 02429233 · $11.1150 Maxalt · DIN 02240520 · not recorded

Shortage status: resolved shortage (ended 2025-01-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02393468

Shortage record checked 2026-09-13T08:10:21.292534+00:00

AG-Rizatriptan ODT · DIN 02492490 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

AG-Rizatriptan ODT · DIN 02492490 Manufacturer: Angita Pharma Inc.; listing date 2021-06-30 Health Canada: Marketed since 2020-11-25 · brand AG-RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Angita pharma inc. · schedule Prescription

Check this DIN again · Health Canada product record

AG-Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98250 · Verify on the e-Formulary ↗ (DIN 02492490)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02492490). DIN 02492490: AG-Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200048; group id 544; item number 1467; lccId None; manufacturer id ANG Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02492490 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98250

Interchangeable products

Accel-Rizatriptan ODT · DIN 02483289 · $7.7800 Apo-Rizatriptan RPD · DIN 02393492 · $11.1150 CCP-Rizatriptan · DIN 02458772 · $11.1150 Co Rizatriptan ODT · DIN 02374749 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465094 · $11.1150 Mar-Rizatriptan ODT · DIN 02462796 · $11.1150 Maxalt RPD · DIN 02240519 · $11.1650 Mint-Rizatriptan ODT · DIN 02439581 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379201 · $11.1150 NRA-Rizatriptan ODT · DIN 02489384 · $11.1150 Nat-Rizatriptan ODT · DIN 02436612 · $11.1650 PMS-Rizatriptan RDT · DIN 02393379 · $11.1150 Rizatriptan ODT · DIN 02442914 · $11.1150 Rizatriptan ODT · DIN 02446138 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351889 · $11.1150 Teva-Rizatriptan ODT · DIN 02396688 · $11.1150

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02492490

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Accel-Rizatriptan ODT · DIN 02483289 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Accel-Rizatriptan ODT · DIN 02483289 Manufacturer: Accel Pharma Inc.; listing date 2020-01-31 Health Canada: Marketed since 2019-10-07 · brand ACCEL-RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Accel pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Accel-Rizatriptan ODT: Formulary list price $7.7800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $7.7800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97372 · Verify on the e-Formulary ↗ (DIN 02483289)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02483289). DIN 02483289: Accel-Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200048; group id 544; item number 1467; lccId None; manufacturer id ACC Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $7.7800; ministry $7.7800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02483289 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97372

Interchangeable products

AG-Rizatriptan ODT · DIN 02492490 · $11.1150 Apo-Rizatriptan RPD · DIN 02393492 · $11.1150 CCP-Rizatriptan · DIN 02458772 · $11.1150 Co Rizatriptan ODT · DIN 02374749 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465094 · $11.1150 Mar-Rizatriptan ODT · DIN 02462796 · $11.1150 Maxalt RPD · DIN 02240519 · $11.1650 Mint-Rizatriptan ODT · DIN 02439581 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379201 · $11.1150 NRA-Rizatriptan ODT · DIN 02489384 · $11.1150 Nat-Rizatriptan ODT · DIN 02436612 · $11.1650 PMS-Rizatriptan RDT · DIN 02393379 · $11.1150 Rizatriptan ODT · DIN 02442914 · $11.1150 Rizatriptan ODT · DIN 02446138 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351889 · $11.1150 Teva-Rizatriptan ODT · DIN 02396688 · $11.1150

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02483289

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Rizatriptan ODT · DIN 02465094 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp-Rizatriptan ODT · DIN 02465094 Manufacturer: Jamp Pharma Corporation; listing date 2018-06-29 Health Canada: Marketed since 2018-02-12 · brand JAMP-RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp-Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95328 · Verify on the e-Formulary ↗ (DIN 02465094)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02465094). DIN 02465094: Jamp-Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200048; group id 544; item number 1467; lccId None; manufacturer id JPC Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02465094 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95328

Interchangeable products

AG-Rizatriptan ODT · DIN 02492490 · $11.1150 Accel-Rizatriptan ODT · DIN 02483289 · $7.7800 Apo-Rizatriptan RPD · DIN 02393492 · $11.1150 CCP-Rizatriptan · DIN 02458772 · $11.1150 Co Rizatriptan ODT · DIN 02374749 · $11.1150 Mar-Rizatriptan ODT · DIN 02462796 · $11.1150 Maxalt RPD · DIN 02240519 · $11.1650 Mint-Rizatriptan ODT · DIN 02439581 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379201 · $11.1150 NRA-Rizatriptan ODT · DIN 02489384 · $11.1150 Nat-Rizatriptan ODT · DIN 02436612 · $11.1650 PMS-Rizatriptan RDT · DIN 02393379 · $11.1150 Rizatriptan ODT · DIN 02442914 · $11.1150 Rizatriptan ODT · DIN 02446138 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351889 · $11.1150 Teva-Rizatriptan ODT · DIN 02396688 · $11.1150

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02465094

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Rizatriptan ODT · DIN 02462796 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mar-Rizatriptan ODT · DIN 02462796 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2018-04-30 Health Canada: Marketed since 2018-02-15 · brand MAR-RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Marcan pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mar-Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95063 · Verify on the e-Formulary ↗ (DIN 02462796)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02462796). DIN 02462796: Mar-Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200048; group id 544; item number 1467; lccId None; manufacturer id MAR Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02462796 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95063

Interchangeable products

AG-Rizatriptan ODT · DIN 02492490 · $11.1150 Accel-Rizatriptan ODT · DIN 02483289 · $7.7800 Apo-Rizatriptan RPD · DIN 02393492 · $11.1150 CCP-Rizatriptan · DIN 02458772 · $11.1150 Co Rizatriptan ODT · DIN 02374749 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465094 · $11.1150 Maxalt RPD · DIN 02240519 · $11.1650 Mint-Rizatriptan ODT · DIN 02439581 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379201 · $11.1150 NRA-Rizatriptan ODT · DIN 02489384 · $11.1150 Nat-Rizatriptan ODT · DIN 02436612 · $11.1650 PMS-Rizatriptan RDT · DIN 02393379 · $11.1150 Rizatriptan ODT · DIN 02442914 · $11.1150 Rizatriptan ODT · DIN 02446138 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351889 · $11.1150 Teva-Rizatriptan ODT · DIN 02396688 · $11.1150

Shortage status: resolved shortage (ended 2020-08-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02462796

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Maxalt RPD · DIN 02240519 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

How long EAP takes

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Savings card: RxHelp ONE lists Maxalt RPD (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Maxalt RPD · DIN 02240519 Manufacturer: Organon Canada Inc.; listing date 2012-03-26 Health Canada: Marketed since 2023-03-06 · brand MAXALT RPD · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Organon canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $11.1650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64090 · Verify on the e-Formulary ↗ (DIN 02240519)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02240519). DIN 02240519: Maxalt RPD Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200048; group id 544; item number 1467; lccId None; manufacturer id OCI Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $23.6888; ministry $11.1650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240519 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64090

Interchangeable products

AG-Rizatriptan ODT · DIN 02492490 · $11.1150 Accel-Rizatriptan ODT · DIN 02483289 · $7.7800 Apo-Rizatriptan RPD · DIN 02393492 · $11.1150 CCP-Rizatriptan · DIN 02458772 · $11.1150 Co Rizatriptan ODT · DIN 02374749 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465094 · $11.1150 Mar-Rizatriptan ODT · DIN 02462796 · $11.1150 Mint-Rizatriptan ODT · DIN 02439581 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379201 · $11.1150 NRA-Rizatriptan ODT · DIN 02489384 · $11.1150 Nat-Rizatriptan ODT · DIN 02436612 · $11.1650 PMS-Rizatriptan RDT · DIN 02393379 · $11.1150 Rizatriptan ODT · DIN 02442914 · $11.1150 Rizatriptan ODT · DIN 02446138 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351889 · $11.1150 Teva-Rizatriptan ODT · DIN 02396688 · $11.1150

Shortage status: resolved shortage (ended 2023-04-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240519

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Rizatriptan ODT · DIN 02379201 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mylan-Rizatriptan ODT · DIN 02379201 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2012-03-26 Health Canada: Marketed since 2012-01-31 · brand MYLAN-RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Mylan pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Mylan-Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86509 · Verify on the e-Formulary ↗ (DIN 02379201)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02379201). DIN 02379201: Mylan-Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200048; group id 544; item number 1467; lccId None; manufacturer id MYL Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02379201 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86509

Interchangeable products

AG-Rizatriptan ODT · DIN 02492490 · $11.1150 Accel-Rizatriptan ODT · DIN 02483289 · $7.7800 Apo-Rizatriptan RPD · DIN 02393492 · $11.1150 CCP-Rizatriptan · DIN 02458772 · $11.1150 Co Rizatriptan ODT · DIN 02374749 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465094 · $11.1150 Mar-Rizatriptan ODT · DIN 02462796 · $11.1150 Maxalt RPD · DIN 02240519 · $11.1650 Mint-Rizatriptan ODT · DIN 02439581 · $11.1150 NRA-Rizatriptan ODT · DIN 02489384 · $11.1150 Nat-Rizatriptan ODT · DIN 02436612 · $11.1650 PMS-Rizatriptan RDT · DIN 02393379 · $11.1150 Rizatriptan ODT · DIN 02442914 · $11.1150 Rizatriptan ODT · DIN 02446138 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351889 · $11.1150 Teva-Rizatriptan ODT · DIN 02396688 · $11.1150

Shortage status: active shortage (reported 2026-02-18, estimated to end 2027-02-09, last updated 2026-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02379201

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Rizatriptan RDT · DIN 02393379 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Rizatriptan RDT · DIN 02393379 Manufacturer: Pharmascience Inc.; listing date 2012-12-21 Health Canada: Marketed since 2012-10-30 · brand PMS-RIZATRIPTAN RDT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Rizatriptan RDT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87860 · Verify on the e-Formulary ↗ (DIN 02393379)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02393379). DIN 02393379: PMS-Rizatriptan RDT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200048; group id 544; item number 1467; lccId None; manufacturer id PMS Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02393379 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87860

Interchangeable products

AG-Rizatriptan ODT · DIN 02492490 · $11.1150 Accel-Rizatriptan ODT · DIN 02483289 · $7.7800 Apo-Rizatriptan RPD · DIN 02393492 · $11.1150 CCP-Rizatriptan · DIN 02458772 · $11.1150 Co Rizatriptan ODT · DIN 02374749 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465094 · $11.1150 Mar-Rizatriptan ODT · DIN 02462796 · $11.1150 Maxalt RPD · DIN 02240519 · $11.1650 Mint-Rizatriptan ODT · DIN 02439581 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379201 · $11.1150 NRA-Rizatriptan ODT · DIN 02489384 · $11.1150 Nat-Rizatriptan ODT · DIN 02436612 · $11.1650 Rizatriptan ODT · DIN 02442914 · $11.1150 Rizatriptan ODT · DIN 02446138 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351889 · $11.1150 Teva-Rizatriptan ODT · DIN 02396688 · $11.1150

Shortage status: resolved shortage (ended 2025-03-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02393379

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rizatriptan ODT · DIN 02442914 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Rizatriptan ODT · DIN 02442914 Manufacturer: Sanis Health Inc.; listing date 2020-08-28 Health Canada: Marketed since 2015-07-23 · brand RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92742 · Verify on the e-Formulary ↗ (DIN 02442914)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02442914). DIN 02442914: Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200048; group id 544; item number 1467; lccId None; manufacturer id SAI Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442914 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92742

Interchangeable products

AG-Rizatriptan ODT · DIN 02492490 · $11.1150 Accel-Rizatriptan ODT · DIN 02483289 · $7.7800 Apo-Rizatriptan RPD · DIN 02393492 · $11.1150 CCP-Rizatriptan · DIN 02458772 · $11.1150 Co Rizatriptan ODT · DIN 02374749 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465094 · $11.1150 Mar-Rizatriptan ODT · DIN 02462796 · $11.1150 Maxalt RPD · DIN 02240519 · $11.1650 Mint-Rizatriptan ODT · DIN 02439581 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379201 · $11.1150 NRA-Rizatriptan ODT · DIN 02489384 · $11.1150 Nat-Rizatriptan ODT · DIN 02436612 · $11.1650 PMS-Rizatriptan RDT · DIN 02393379 · $11.1150 Rizatriptan ODT · DIN 02446138 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351889 · $11.1150 Teva-Rizatriptan ODT · DIN 02396688 · $11.1150

Shortage status: resolved shortage (ended 2025-02-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442914

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rizatriptan ODT · DIN 02446138 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Rizatriptan ODT · DIN 02446138 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30 Health Canada: Marketed since 2018-02-13 · brand RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93139 · Verify on the e-Formulary ↗ (DIN 02446138)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02446138). DIN 02446138: Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200048; group id 544; item number 1467; lccId None; manufacturer id SIV Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02446138 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93139

Interchangeable products

AG-Rizatriptan ODT · DIN 02492490 · $11.1150 Accel-Rizatriptan ODT · DIN 02483289 · $7.7800 Apo-Rizatriptan RPD · DIN 02393492 · $11.1150 CCP-Rizatriptan · DIN 02458772 · $11.1150 Co Rizatriptan ODT · DIN 02374749 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465094 · $11.1150 Mar-Rizatriptan ODT · DIN 02462796 · $11.1150 Maxalt RPD · DIN 02240519 · $11.1650 Mint-Rizatriptan ODT · DIN 02439581 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379201 · $11.1150 NRA-Rizatriptan ODT · DIN 02489384 · $11.1150 Nat-Rizatriptan ODT · DIN 02436612 · $11.1650 PMS-Rizatriptan RDT · DIN 02393379 · $11.1150 Rizatriptan ODT · DIN 02442914 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351889 · $11.1150 Teva-Rizatriptan ODT · DIN 02396688 · $11.1150

Shortage status: resolved shortage (ended 2018-02-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02446138

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Rizatriptan ODT · DIN 02351889 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Rizatriptan ODT · DIN 02351889 Manufacturer: Sandoz Canada Inc.; listing date 2012-03-26 Health Canada: Marketed since 2012-01-30 · brand SANDOZ RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83712 · Verify on the e-Formulary ↗ (DIN 02351889)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02351889). DIN 02351889: Sandoz Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200048; group id 544; item number 1467; lccId None; manufacturer id SDZ Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351889 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83712

Interchangeable products

AG-Rizatriptan ODT · DIN 02492490 · $11.1150 Accel-Rizatriptan ODT · DIN 02483289 · $7.7800 Apo-Rizatriptan RPD · DIN 02393492 · $11.1150 CCP-Rizatriptan · DIN 02458772 · $11.1150 Co Rizatriptan ODT · DIN 02374749 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465094 · $11.1150 Mar-Rizatriptan ODT · DIN 02462796 · $11.1150 Maxalt RPD · DIN 02240519 · $11.1650 Mint-Rizatriptan ODT · DIN 02439581 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379201 · $11.1150 NRA-Rizatriptan ODT · DIN 02489384 · $11.1150 Nat-Rizatriptan ODT · DIN 02436612 · $11.1650 PMS-Rizatriptan RDT · DIN 02393379 · $11.1150 Rizatriptan ODT · DIN 02442914 · $11.1150 Rizatriptan ODT · DIN 02446138 · $11.1150 Teva-Rizatriptan ODT · DIN 02396688 · $11.1150

Shortage status: resolved shortage (ended 2025-03-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02351889

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Rizatriptan ODT · DIN 02396688 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Rizatriptan ODT · DIN 02396688 Manufacturer: Teva Canada Limited; listing date 2014-12-18 Health Canada: Marketed since 2014-11-04 · brand TEVA-RIZATRIPTAN ODT · ATC N02CC04 RIZATRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Rizatriptan ODT: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88171 · Verify on the e-Formulary ↗ (DIN 02396688)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02396688). DIN 02396688: Teva-Rizatriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200048; group id 544; item number 1467; lccId None; manufacturer id TEV Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02396688 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88171

Interchangeable products

AG-Rizatriptan ODT · DIN 02492490 · $11.1150 Accel-Rizatriptan ODT · DIN 02483289 · $7.7800 Apo-Rizatriptan RPD · DIN 02393492 · $11.1150 CCP-Rizatriptan · DIN 02458772 · $11.1150 Co Rizatriptan ODT · DIN 02374749 · $11.1150 Jamp-Rizatriptan ODT · DIN 02465094 · $11.1150 Mar-Rizatriptan ODT · DIN 02462796 · $11.1150 Maxalt RPD · DIN 02240519 · $11.1650 Mint-Rizatriptan ODT · DIN 02439581 · $11.1150 Mylan-Rizatriptan ODT · DIN 02379201 · $11.1150 NRA-Rizatriptan ODT · DIN 02489384 · $11.1150 Nat-Rizatriptan ODT · DIN 02436612 · $11.1650 PMS-Rizatriptan RDT · DIN 02393379 · $11.1150 Rizatriptan ODT · DIN 02442914 · $11.1150 Rizatriptan ODT · DIN 02446138 · $11.1150 Sandoz Rizatriptan ODT · DIN 02351889 · $11.1150

Shortage status: resolved shortage (ended 2026-01-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02396688

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Act Rizatriptan · DIN 02381702 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Act Rizatriptan · DIN 02381702 Manufacturer: Teva Canada Limited; listing date 2012-08-27 Health Canada: Marketed since 2020-05-06 · brand ACT RIZATRIPTAN · ATC N02CC04 RIZATRIPTAN · form Tablet · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Act Rizatriptan: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86756 · Verify on the e-Formulary ↗ (DIN 02381702)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02381702). DIN 02381702: Act Rizatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200046; group id 544; item number 1469; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381702 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86756

Interchangeable products

Apo-Rizatriptan · DIN 02393476 · $11.1150 Auro-Rizatriptan · DIN 02441144 · $11.1150 Jamp-Rizatriptan · DIN 02380463 · $11.1150 Jamp-Rizatriptan IR · DIN 02429241 · $11.1150 Mar-Rizatriptan · DIN 02379678 · $11.1150 Maxalt · DIN 02240521 · $11.1150 Rizatriptan · DIN 02516756 · $11.1150

Shortage status: resolved shortage (ended 2025-01-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02381702

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Rizatriptan · DIN 02393476 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Maxalt, Maxalt RPD; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 126, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Rizatriptan · DIN 02393476 Manufacturer: Apotex Inc.; listing date 2012-12-21 Health Canada: Marketed since 2013-03-06 · brand APO-RIZATRIPTAN · ATC N02CC04 RIZATRIPTAN · form Tablet · route Oral · ingredients RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Rizatriptan: Formulary list price $11.1150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87869 · Verify on the e-Formulary ↗ (DIN 02393476)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02393476). DIN 02393476: Apo-Rizatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200046; group id 544; item number 1469; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.1150; ministry $11.1150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02393476 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87869

Interchangeable products

Act Rizatriptan · DIN 02381702 · $11.1150 Auro-Rizatriptan · DIN 02441144 · $11.1150 Jamp-Rizatriptan · DIN 02380463 · $11.1150 Jamp-Rizatriptan IR · DIN 02429241 · $11.1150 Mar-Rizatriptan · DIN 02379678 · $11.1150 Maxalt · DIN 02240521 · $11.1150 Rizatriptan · DIN 02516756 · $11.1150

Shortage status: resolved shortage (ended 2026-04-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02393476

Shortage record checked 2026-09-13T08:10:21.292534+00:00

RIZATRIPTAN

Accel-Rizatriptan ODT · DIN 02483270 · 5mg · Orally Disintegrating tablet

Jamp-Rizatriptan ODT · DIN 02465086 · 5mg · Orally Disintegrating tablet

Mar-Rizatriptan ODT · DIN 02462788 · 5mg · Orally Disintegrating tablet

Maxalt RPD · DIN 02240518 · 5mg · Orally Disintegrating tablet

Mylan-Rizatriptan ODT · DIN 02379198 · 5mg · Orally Disintegrating tablet

PMS-Rizatriptan RDT · DIN 02393360 · 5mg · Orally Disintegrating tablet

Rizatriptan ODT · DIN 02442906 · 5mg · Orally Disintegrating tablet

Rizatriptan ODT · DIN 02446111 · 5mg · Orally Disintegrating tablet

Sandoz Rizatriptan ODT · DIN 02351870 · 5mg · Orally Disintegrating tablet

Teva-Rizatriptan ODT · DIN 02396661 · 5mg · Orally Disintegrating tablet

Apo-Rizatriptan · DIN 02393468 · 5mg · tablet

AG-Rizatriptan ODT · DIN 02492490 · 10mg · Orally Disintegrating tablet

Accel-Rizatriptan ODT · DIN 02483289 · 10mg · Orally Disintegrating tablet

Jamp-Rizatriptan ODT · DIN 02465094 · 10mg · Orally Disintegrating tablet

Mar-Rizatriptan ODT · DIN 02462796 · 10mg · Orally Disintegrating tablet

Maxalt RPD · DIN 02240519 · 10mg · Orally Disintegrating tablet

Mylan-Rizatriptan ODT · DIN 02379201 · 10mg · Orally Disintegrating tablet

PMS-Rizatriptan RDT · DIN 02393379 · 10mg · Orally Disintegrating tablet

Rizatriptan ODT · DIN 02442914 · 10mg · Orally Disintegrating tablet

Rizatriptan ODT · DIN 02446138 · 10mg · Orally Disintegrating tablet

Sandoz Rizatriptan ODT · DIN 02351889 · 10mg · Orally Disintegrating tablet

Teva-Rizatriptan ODT · DIN 02396688 · 10mg · Orally Disintegrating tablet

Act Rizatriptan · DIN 02381702 · 10mg · tablet

Apo-Rizatriptan · DIN 02393476 · 10mg · tablet

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Availability

Prepare an Exceptional Access request

Rizatriptan (Maxalt, Maxalt RPD)

Other review policies